NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer

NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for the treatment of melanoma in patients post-surgery, it has been announced.

read more